150 related articles for article (PubMed ID: 35018520)
21. Safety of ondansetron loading doses in children with cancer.
Hasler SB; Hirt A; Ridolfi Luethy A; Leibundgut KK; Ammann RA
Support Care Cancer; 2008 May; 16(5):469-75. PubMed ID: 17940810
[TBL] [Abstract][Full Text] [Related]
22. Results of a compassionate-use program using intravenous ondansetron to prevent nausea and vomiting in patients receiving emetogenic cancer chemotherapy.
Berry WR; House KW; Lee JT; Plagge PB; Meshad MW; Grapski R
Semin Oncol; 1992 Dec; 19(6 Suppl 15):33-7. PubMed ID: 1485180
[TBL] [Abstract][Full Text] [Related]
23. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Lindley C; Goodin S; McCune J; Kane M; Amamoo MA; Shord S; Pham T; Yowell S; Laliberte K; Schell M; Bernard S; Socinski MA
Am J Clin Oncol; 2005 Jun; 28(3):270-6. PubMed ID: 15923800
[TBL] [Abstract][Full Text] [Related]
24. Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children.
Matera MG; Di Tullio M; Lucarelli C; Casale F; Calabria C; Lampa E; Indolfi P; Rossi F
J Med; 1993; 24(2-3):161-70. PubMed ID: 7691978
[TBL] [Abstract][Full Text] [Related]
25. A narrative review of tropisetron and palonosetron for the control of chemotherapy-induced nausea and vomiting.
Yang Y; Zhang L
Chin Clin Oncol; 2020 Apr; 9(2):17. PubMed ID: 31865713
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenetics of Postoperative Nausea and Vomiting.
Aroke EN; Hicks TL
J Perianesth Nurs; 2019 Dec; 34(6):1088-1105. PubMed ID: 31227296
[TBL] [Abstract][Full Text] [Related]
27. The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit.
Ng WL; Della-Fiorentina SA
Eur J Cancer Care (Engl); 2010 May; 19(3):403-7. PubMed ID: 19686353
[TBL] [Abstract][Full Text] [Related]
28. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
[TBL] [Abstract][Full Text] [Related]
29. Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Gebbia V; Testa A; Cannata G; Gebbia N
Anticancer Drugs; 1996 Sep; 7(7):734-7. PubMed ID: 8949983
[TBL] [Abstract][Full Text] [Related]
30. Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
Siddique R; Hafiz MG; Rokeya B; Jamal CY; Islam A
Mymensingh Med J; 2011 Oct; 20(4):680-8. PubMed ID: 22081189
[TBL] [Abstract][Full Text] [Related]
31. Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV).
Choi MR; Jiles C; Seibel NL
J Pediatr Hematol Oncol; 2010 Oct; 32(7):e268-71. PubMed ID: 20736848
[TBL] [Abstract][Full Text] [Related]
32. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Tienchaiananda P; Nipondhkit W; Maneenil K; Sa-Nguansai S; Payapwattanawong S; Laohavinij S; Maneechavakajorn J
Ann Palliat Med; 2019 Sep; 8(4):372-380. PubMed ID: 31500422
[TBL] [Abstract][Full Text] [Related]
33. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Pater JL; Lofters WS; Zee B; Dempsey E; Walde D; Moquin JP; Wilson K; Hoskins P; Guevin RM; Verma S; Navari R; Krook JE; Hainsworth J; Palmer M; Chin C
Ann Oncol; 1997 Feb; 8(2):181-5. PubMed ID: 9093728
[TBL] [Abstract][Full Text] [Related]
34. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
35. Ondansetron and metoclopramide as second-line antiemetics in women with nausea and vomiting in pregnancy: the EMPOWER pilot factorial RCT.
Robson S; McParlin C; Mossop H; Lie M; Fernandez-Garcia C; Howel D; Graham R; Ternent L; Steel A; Goudie N; Nadeem A; Phillipson J; Shehmar M; Simpson N; Tuffnell D; Campbell I; Williams R; O'Hara ME; McColl E; Nelson-Piercy C
Health Technol Assess; 2021 Nov; 25(63):1-116. PubMed ID: 34782054
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.
Nakagaki M; Barras M; Curley C; Butler JP; Kennedy GA
Support Care Cancer; 2017 Feb; 25(2):607-613. PubMed ID: 27738796
[TBL] [Abstract][Full Text] [Related]
37. The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning.
Clark RF; Chen R; Williams SR; Johnson CL; Harchelroad F
J Toxicol Clin Toxicol; 1996; 34(2):163-7. PubMed ID: 8618249
[TBL] [Abstract][Full Text] [Related]
38. Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy.
Tsuji D; Matsumoto M; Kawasaki Y; Kim YL; Yamamoto K; Nakamichi H; Sahara Y; Makuta R; Yokoi M; Miyagi T; Itoh K
Cancer Chemother Pharmacol; 2021 Jan; 87(1):73-83. PubMed ID: 33099677
[TBL] [Abstract][Full Text] [Related]
39. The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Vimolchalao V; Sakdejayont S; Wongchanapai P; Sukprakun S; Angspatt P; Thawinwisan W; Chenaksara P; Sriuranpong V; Vinayanuwatikun C; Parinyanitikun N; Poovorawan N; Tanasanvimon S
Int J Clin Oncol; 2020 Feb; 25(2):396-402. PubMed ID: 31776732
[TBL] [Abstract][Full Text] [Related]
40. Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
Mitchell PL; Evans BD; Allan SG; Forgeson GV; Mak D; Neave L; Humm G; Langley G; Dickson D; Harvey VJ
N Z Med J; 1992 Mar; 105(929):73-5. PubMed ID: 1532054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
